
Morningside is a private investment group founded in 1986 by the Chan family of Hong Kong. The firm makes venture capital and private equity investments in companies with novel science and technology, characterized by a long-term outlook in company-building.
Average disclosed round size is $61.7M (across 176 rounds with reported amounts).
Portfolio
139
Fund Size
—
Top Stage
Series B
Last 12 Mo
5
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
204 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Series A | $5M | Jul 2026 | |
| Series A | $10.8M | Apr 2026 | |
| Series C | $105M | Mar 2026 | |
| Seed | $8.5M | Oct 2025 | |
| Series B | $28M | Oct 2025 | |
| CCyted Health | Series B | $44M | Sep 2025 |
| Series B | $12M | Mar 2025 | |
| Seed | $4M | Feb 2025 | |
| Series C | $105M | Jan 2025 | |
| Series C | — | Jan 2025 | |
| Series C | $112M | Jan 2025 | |
| Series B | $44M | Jan 2025 | |
| CCyted Health | Unknown | $44M | Jan 2025 |
| Series B | — | Jan 2025 | |
| AAlentis | Series D | $181.4M | Nov 2024 |
| Seed | $5M | Apr 2024 | |
| AAlamar Biosciences, Inc. | Series C | $128M | Feb 2024 |
| Series A | $24M | Jan 2024 | |
| FF2G | Series H | $100M | Jan 2024 |
| Series C | $125M | Jan 2024 | |
| Series D | $181.4M | Jan 2024 | |
| Series C | $125M | Jan 2024 | |
| Series B | $30M | Dec 2023 | |
| EEpigenic Therapeutics | Series A | $32M | Aug 2023 |
| Series A | $32M | Aug 2023 |
Page 1 of 9
Top Co-Investors
General Catalyst17 shared
OrbiMed13 shared
Fidelity Investments8 shared
Forbion8 shared
Sofinnova Partners8 shared
Legend Capital7 shared
Lightspeed Venture Partners7 shared
Frazier Healthcare Partners7 shared
Shunwei Capital6 shared
BGF6 shared
Boston Seed Capital5 shared
Visible Ventures5 shared
Golden Ventures5 shared
Matrix Partners5 shared
Polaris Partners5 shared
Novo Capital5 shared
Bpifrance5 shared
Jeito Capital5 shared
High-Tech Gründerfonds5 shared
Last updated: 20 October 2026